Ledraxen

Enoxaparin sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile solution for subcutaneous, intravenous and haemodialysis use. It prevents and treats thromboembolic disorders in patients at risk of clot formation.

GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ledraxen (enoxaparin sodium) is used in the anticoagulation pathway to prevent and treat venous thromboembolism.

- Deep vein thrombosis (DVT) prevention: reduces the risk of clot formation in at‑risk patients. - Acute deep vein thrombosis treatment: limits clot extension and recurrence. - Pulmonary embolism prevention and treatment: stops clot migration to the lungs and resolves existing emboli. - Anticoagulation during haemodialysis: maintains circuit patency and minimizes clotting during the procedure.

Adverse reactions may occur with enoxaparin sodium therapy.

Common Side Effects: - Injection site pain or bruising: mild local discomfort at the injection site. - Minor bleeding: such as epistaxis, gum bleeding, or easy bruising. - Nausea or vomiting: gastrointestinal upset in some patients. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Major bleeding: life‑threatening hemorrhage including intracranial or gastrointestinal bleeding. - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet drop with paradoxical clot risk. - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Spinal or epidural hematoma: bleeding in the spinal canal after neuraxial procedures.

Use of Ledraxen requires careful clinical assessment and monitoring.

- Renal impairment: adjust dose or avoid in severe renal dysfunction. - Pregnancy: Category B; use only when benefit outweighs potential risk. - Surgery or invasive procedures: discontinue appropriately to reduce bleeding risk. - Concomitant anticoagulants or antiplatelet agents: increased risk of hemorrhage; monitor closely. - Platelet monitoring: watch for thrombocytopenia, especially HIT. - Store below 25°C: keep in original carton, protect from moisture and light.

Enoxaparin sodium can interact with several drug classes, affecting bleeding risk.

Major Interactions (Avoid): - Concurrent use with other systemic anticoagulants (e.g., warfarin, direct thrombin inhibitors): may cause severe bleeding. - Neuraxial anesthesia or spinal puncture: heightened risk of spinal/epidural hematoma.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (aspirin, clopidogrel): increase bleeding tendency. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate gastrointestinal bleeding. - Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): can potentiate bleeding risk.